Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
REPL
REPL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
REPL News
REPL Faces Pressure After FDA Issues Second Complete Response Letter
6d ago
stocktwits
Replimune Faces FDA CRL for RP1 Melanoma Therapy Amid Analyst Downgrades
6d ago
Newsfilter
Replimune Shares Hit All-Time Low After FDA Rejection
6d ago
seekingalpha
Trump Threatens 50% Tariff on China Amid Trade Tensions
6d ago
Fool
Replimune's RP-1 Faces Second FDA Rejection, Shares Plunge
6d ago
stocktwits
U.S. Stock Futures Drop as Oil Prices Surge Above $100 Amid Iran Tensions
6d ago
seekingalpha
Replimune Shares Plunge 56% After FDA Rejects RP1 Approval
Apr 13 2026
seekingalpha
Replimune Faces FDA Rejection for RP1 Application
Apr 13 2026
NASDAQ.COM
REPLIMUNE GROUP INC: JP MORGAN Downgrades Rating to Underweight from Neutral
Apr 13 2026
moomoo
REPLIMUNE GROUP INC: PIPER SANDLER LOWERS RATING TO NEUTRAL AND REDUCES TARGET PRICE FROM $14 TO $4
Apr 13 2026
moomoo
Replimune Cuts Workforce After FDA Rejects RP1 Approval
Apr 11 2026
seekingalpha
IOVA Benefits from Rival Drug Rejection, Analysts Bullish
Apr 10 2026
stocktwits
Replimune Faces FDA Rejection for RP1 Application
Apr 10 2026
Newsfilter
REPLIMUNE INITIATES IGNYTE-3 IN RESPONSE TO FDA INPUT TO MEET REGULATORY REQUIREMENT FOR CONFIRMATORY STUDY IN ACCELERATED APPROVAL PROCESS
Apr 10 2026
moomoo
REPLIMUNE GROUP ANNOUNCES NECESSARY JOB CUTS AND SIGNIFICANT REDUCTION OF U.S. MANUFACTURING OPERATIONS
Apr 10 2026
moomoo
REPLIMUNE GROUP: DISPUTES FDA'S VIEW ON ADEQUACY OF RP1 BLA DATA FOR ADVANCED CANCER PATIENT ACCESS
Apr 10 2026
moomoo
Show More News
